GLP Watchdog

Hims vs Willow

Hims has an open FDA warning letter dated September 9, 2025. Willow has none. No price lines up like for like: Hims and Willow publish prices for different products.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Hims / Willow

Hims logo

Hims

6.7/10

Willow logo

Willow

7.3/10

FDA warning letters
None on record
Pharmacy
Lowest standing price
$149/moBrand-name semaglutide pill, medication only, membership extra
$299/moCompounded semaglutide injection
States
All 50 states
35 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked September 2026
Visit Hims
Visit Willow

Neither Hims nor Willow pays us. Links to them earn nothing. Scores: Hims 6.7, Willow 7.3. How we are paid

What the record shows

  1. 01

    Hims has an open FDA warning letter dated September 9, 2025. Willow has none.

  2. 02

    Willow names five pharmacies. Hims sells brand-name medication only.

  3. 03

    No price lines up like for like: Hims and Willow publish prices for different products.

  4. 04

    Only Hims lists a price for brand-name semaglutide pen, brand-name tirzepatide pen and brand-name semaglutide pill. Only Willow lists a price for compounded semaglutide injection and compounded tirzepatide injection.

  5. 05

    Hims covers 15 states Willow does not.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Hims

Willow

Compounded semaglutide injection
Not sold or not priced

$299/mo

$3,588 a year

Compounded tirzepatide injection
Not sold or not priced

$399/mo

$4,788 a year

Brand-name semaglutide pen

$199/mo

medication only, membership extra; not compared

Not sold or not priced
Brand-name tirzepatide pen

$299/mo

medication only, membership extra; not compared

Not sold or not priced
Brand-name semaglutide pill

$149/mo

medication only, membership extra; not compared

Not sold or not priced
Foundayo (orforglipron) pill

$149/mo

medication only, membership extra; not compared

Not sold or not priced
Price includes
Medication
Medication, clinician visits, shipping
Billed separately
Clinician visits, coaching
Not stated
Cancel any time
Yes, stated
Yes, stated
Minimum term
Monthly membership, auto-renews
None
Refunds
First month's membership fee is non-refundable; partial-period refunds are not guaranteed
Full refund if you cancel before the prescription is sent to the pharmacy; none once the medication is compounded
Early-exit fee
None stated
Not stated

Read off each seller’s own pages. Hims: October 17, 2026. Willow: July 10, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Hims

6.7/10
  • Sells brand-name semaglutide pen and brand-name tirzepatide pen, which Willow does not price
  • Lists 50 states against 35
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
  • Lowest price covers the medication only, with a separate membership on top
Visit Hims

The case for Willow

7.3/10
  • No FDA warning letter on record
  • Sells compounded semaglutide injection and compounded tirzepatide injection, which Hims does not price
  • Price includes clinician visits
Visit Willow

Scores

Hims 6.7 · Willow 7.3 out of 10. Six weighted parts.

Value25%

3.0A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
9.0

Accessibility10%

10.0A
vs
B
7.6

Support10%

3.0A
vs
B
7.0

The score is the same formula for every seller. Payment does not enter it. Method

Hims vs Willow: questions

Hims has an open FDA warning letter dated September 9, 2025. Willow has none. Letters are matched to a seller by company, domain and address, never by a similar name.
Willow names five pharmacies. Hims sells brand-name medication only. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
No price lines up like for like: Hims and Willow publish prices for different products. We only set two prices against each other when they are for the same product and both are standing month-to-month or 4-week rates.
Hims states you can cancel at any time; refunds: first month's membership fee is non-refundable; partial-period refunds are not guaranteed. Willow states you can cancel at any time; refunds: full refund if you cancel before the prescription is sent to the pharmacy; none once the medication is compounded.
Neither Hims nor Willow pays us. Links to them earn nothing. Scores: Hims 6.7, Willow 7.3.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks